Published in CPT Pharmacometrics Syst Pharmacol on April 16, 2014
Model-Based Individualized Treatment of Chemotherapeutics: Bayesian Population Modeling and Dose Optimization. PLoS One (2015) 0.82
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics (2015) 0.78
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 32.05
Structural variation in the human genome. Nat Rev Genet (2006) 21.40
Using Bayesian networks to analyze expression data. J Comput Biol (2000) 15.98
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (2011) 15.45
Stochasticity in gene expression: from theories to phenotypes. Nat Rev Genet (2005) 14.39
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Noise propagation in gene networks. Science (2005) 8.19
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature (2009) 7.24
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Robustness of cellular functions. Cell (2004) 6.65
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell (2008) 6.62
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med (1998) 6.14
A whole-cell computational model predicts phenotype from genotype. Cell (2012) 5.98
Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) (2001) 4.88
Oscillations and variability in the p53 system. Mol Syst Biol (2006) 4.59
Network-based prediction of human tissue-specific metabolism. Nat Biotechnol (2008) 4.39
In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66
Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res (2004) 3.46
Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 3.45
Variability and robustness in T cell activation from regulated heterogeneity in protein levels. Science (2008) 3.38
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells (1998) 3.13
Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther (2012) 2.77
Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol Syst Biol (2010) 2.60
Measurement of single-cell dynamics. Nature (2010) 2.55
Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther (1989) 2.51
Interactome modeling. FEBS Lett (2005) 2.41
Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy (2008) 2.34
Genetic instability induced by the tumor microenvironment. Cancer Res (1996) 2.33
Origins of regulated cell-to-cell variability. Nat Rev Mol Cell Biol (2011) 2.15
Importance of input perturbations and stochastic gene expression in the reverse engineering of genetic regulatory networks: insights from an identifiability analysis of an in silico network. Genome Res (2003) 2.09
HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol Syst Biol (2010) 2.05
Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr Opin Chem Biol (2009) 2.05
Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med (2013) 2.00
An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci (2008) 1.89
Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther (1987) 1.62
On the holistic approach in cellular and cancer biology: nonlinearity, complexity, and quasi-determinism of the dynamic cellular network. J Surg Oncol (1998) 1.60
Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol (2001) 1.56
In silico cancer modeling: is it ready for prime time? Nat Clin Pract Oncol (2008) 1.52
Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J (2006) 1.42
Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia (2008) 1.33
Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am J Pharmacogenomics (2003) 1.28
Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics (1992) 1.26
Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A (2005) 1.24
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer (2008) 1.18
Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol (2013) 1.14
Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet? Hematology Am Soc Hematol Educ Program (2006) 1.13
Genome-scale metabolic networks. Wiley Interdiscip Rev Syst Biol Med (2010) 1.11
Analytical approaches to metabolomics and applications to systems biology. Semin Nephrol (2010) 1.08
Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics (2011) 1.07
In silico model-driven assessment of the effects of single nucleotide polymorphisms (SNPs) on human red blood cell metabolism. Genome Res (2002) 1.02
Integrating cellular metabolism into a multiscale whole-body model. PLoS Comput Biol (2012) 1.01
Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther (1983) 1.00
Pharmacogenetics and coumarin dosing--recalibrating expectations. N Engl J Med (2013) 0.99
Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics (2005) 0.99
Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol (1995) 0.92
Pharmacogenomics: the promise of personalized medicine. Environ Health Perspect (2003) 0.92
Pharmacometabonomics and personalized medicine. Ann Clin Biochem (2013) 0.89
Bistability versus bimodal distributions in gene regulatory processes from population balance. PLoS Comput Biol (2011) 0.88
Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population. Eur J Clin Pharmacol (1993) 0.84
Integrating cybernetic modeling with pathway analysis provides a dynamic, systems-level description of metabolic control. Biotechnol Bioeng (2008) 0.83
Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur J Gastroenterol Hepatol (2004) 0.79
The promises of personalized medicine. Eur J Clin Pharmacol (2010) 0.78
Cybernetic models based on lumped elementary modes accurately predict strain-specific metabolic function. Biotechnol Bioeng (2011) 0.77
Segregation analysis of human red blood cell thiopurine methyltransferase activity. Genet Epidemiol (1995) 0.77
The SmartAmp method: rapid detection of SNPs in thiopurine S-methyltransferase and ABC transporters ABCC4 and ABCG2. Curr Drug Metab (2012) 0.76